Adénocarcinome bronchique avec mutation de l'EGFR et réarrangement ALKÂ concomitants

Therapeutic strategy needs to be clarified in cases of double alteration. With regard to the second patient, appearance of ALK rearrangement may constitute a resistance mechanism to EGFR's TKI.